Fig. 6: Anti-Q586B2 Nbs exert a Q586B2-blocking potential on myeloid cells (BMDMs) in vitro as well as a therapeutic potential.
a BMDMs generated from C57BL/6 mice (2 × 105 cells/well) were incubated with 1 µg/ml of LPS-free Q586B2 (white bars) or buffer alone (black bars in presence or absence of anti-Q586B2 Nbs (5 µg/ml)). After 48 h incubation the culture medium was tested for IL-10 production. Negative controls: cells incubated with buffer alone or without any protein. Dashed red line represent levels of cytokines produced by BMDMs stimulated with Q586B2 alone and all groups were compared to this signal. Data are shown as means ± SEM and representative of 2 independent experiments (n = 3). Analysis was performed using a one-way ANOVA with Brown–Forsythe and Welch’s test (only significance p < 0.05 is shown). b, c Parasitemia development and survival of C57BL/6 mice infected with Wild-type T. b. brucei AnTat1.1E parasites and treated with non-blocking anti-Q586B2 Nbs (blue box) or blocking anti-Q586B2 Nbs (orange box) starting from days 0 post-infection and this for 4 consecutive days (indicated by blue arrows). Results are presented as mean (parasitemia) or median (survival) of 5 individual mice ± SEM. Parasitemia was analyzed using a Mann–Whitney U-test (only significance p < 0.05 is shown) and survival curves were analyzed via a Mantel–Cox test (MS median survival). Source data are provided as a Source Data file.
